- Title
-
Pharmacological activation of lysophosphatidic acid receptors regulates erythropoiesis
- Authors
- Lin, K.H., Ho, Y.H., Chiang, J.C., Li, M.W., Lin, S.H., Chen, W.M., Chiang, C.L., Lin, Y.N., Yang, Y.J., Chen, C.N., Lu, J., Huang, C.J., Tigyi, G., Yao, C.L., Lee, H.
- Source
- Full text @ Sci. Rep.
Characterization of the function of LPA3 during primitive erythropoiesis in zebrafish embryos. Zebrafish embryos were immersed in (a) the LPA1/3 antagonist Ki16425 or (b) the LPA3 agonist 2S-OMPT for 48 h. O-dianisidine staining was classified as normal, moderate, or severe based on the expression level of embryonic blood in the CHT region. The right-hand panel shows the quantitative results. (c) Whole-mount in situ hybridization showed the mRNA expression of α-A1, β-E1 globin and ikaros in zLPAR3 tMO-injected or wild type embryos. |
Analysis of the roles of LPA3 during definitive erythropoiesis in zebrafish. (a) O-dianisidine staining showed the effects of LPAR3 mRNA, 2S-OMPT, and LPAR3-MO during definitive erythropoiesis at 96 hpf in the CHT region. (b) The quantitative results for (a). (c) A whole-mount in situ hybridization showing the mRNA expression levels of α-E1 and β-E1 in the wild-type, LPAR3-MO, and 2S-OMPT treatment groups. |
Characterization of the effects of LPA2 during definitive erythropoiesis. The effects of LPAR2 MO revealed defective erythropoiesis in the CHT region based on o-dianisidine staining. (b) The quantitative results for (a). (c) The effects of the LPA2 agonist GRI after treatment for 96 h. O-dianisidine staining levels were classified as normal, moderate, or defective based on the expression levels in the embryonic blood. (d) The quantification hemoglobin expression after treatment with different concentrations of GRI for four days. PHENOTYPE:
|